What are residual symptoms in schizophrenia spectrum disorder? Clinical description and 1-year persistence within a naturalistic trial
The aim of this study was to evaluate residual symptoms in patients achieving remission according to the consensus criteria and to analyze their potential influence on the patient’s outcome one year after discharge. In total, 399 patients suffering from a schizophrenia spectrum disorder were evaluat...
Gespeichert in:
| Veröffentlicht in: | European archives of psychiatry and clinical neuroscience 2015-03, Vol.265 (2), p.107-116 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 116 |
|---|---|
| container_issue | 2 |
| container_start_page | 107 |
| container_title | European archives of psychiatry and clinical neuroscience |
| container_volume | 265 |
| creator | Schennach, Rebecca Riedel, Michael Obermeier, Michael Spellmann, Ilja Musil, Richard Jäger, Markus Schmauss, Max Laux, Gerd Pfeiffer, Herbert Naber, Dieter Schmidt, Lutz G. Gaebel, Wolfgang Klosterkötter, Joachim Heuser, Isabella Maier, Wolfgang Lemke, Matthias R. Rüther, Eckart Klingberg, Stefan Gastpar, Markus Möller, Hans-Jürgen |
| description | The aim of this study was to evaluate residual symptoms in patients achieving remission according to the consensus criteria and to analyze their potential influence on the patient’s outcome one year after discharge. In total, 399 patients suffering from a schizophrenia spectrum disorder were evaluated within a naturalistic study. Remission status was examined using the consensus criteria. Residual symptoms were defined as any symptom present at the time-point of remission following analogous analyses performed in depressed patients. Therefore, a PANSS item with a symptom severity of >1 (= at least borderline mentally ill) was defined to be a residual symptom. Remitters with and without residual symptoms were compared regarding psychopathology, functioning and side effects. In total, 236 patients (59 %) were remitters at discharge with 94 % of them suffering from at least one residual symptom. The most common residual symptoms were blunted affect (49 %), conceptual disorganization (42 %) and social withdrawal (40 %). A significant association was found between the presence of residual symptoms and the severity of side effects (
p
|
| doi_str_mv | 10.1007/s00406-014-0528-2 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1664215109</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1664215109</sourcerecordid><originalsourceid>FETCH-LOGICAL-c475t-cd988d885d74faf535de1119f22d7c1b2aba97c4c755ac8910f399313ea2fa023</originalsourceid><addsrcrecordid>eNqNkU2LFDEQhoMo7rj6A7xIwIuXdqvSSX-cRAa_YGEvisemJkk7WbrTbSrNMv4Af_f2OKuIIOypIPW8bxIeIZ4jvEaA-oIBNFQFoC7AqKZQD8QGdVkWjW7xodhAq6HAstRn4gnzNQCgUfBYnCmjKlQIG_Hz656ypORl8hzcQoPkwzjnaWQZomS7Dz-meZ98DCR59janZZQu8JScT2_kdggx2DXlPNsU5hymKCk6icXBU5KzTxw4-2i9vAl5v3aSjJSXRMN6HqzMKdDwVDzqaWD_7G6eiy_v333efiwurz582r69LKyuTS6sa5vGNY1xte6pN6VxHhHbXilXW9wp2lFbW21rY8g2LUJftm2JpSfVE6jyXLw69c5p-r54zt0Y2PphoOinhTusKq3QILT3QE1TQ6XMEX35D3o9LSmuH_lFrW5MY1YKT5RNE3PyfTenMFI6dAjd0Wd38tmtPrujz-743hd3zctu9O5P4rfAFVAngNdV_ObTX1f_t_UWRZmsUA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1658052585</pqid></control><display><type>article</type><title>What are residual symptoms in schizophrenia spectrum disorder? Clinical description and 1-year persistence within a naturalistic trial</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Schennach, Rebecca ; Riedel, Michael ; Obermeier, Michael ; Spellmann, Ilja ; Musil, Richard ; Jäger, Markus ; Schmauss, Max ; Laux, Gerd ; Pfeiffer, Herbert ; Naber, Dieter ; Schmidt, Lutz G. ; Gaebel, Wolfgang ; Klosterkötter, Joachim ; Heuser, Isabella ; Maier, Wolfgang ; Lemke, Matthias R. ; Rüther, Eckart ; Klingberg, Stefan ; Gastpar, Markus ; Möller, Hans-Jürgen</creator><creatorcontrib>Schennach, Rebecca ; Riedel, Michael ; Obermeier, Michael ; Spellmann, Ilja ; Musil, Richard ; Jäger, Markus ; Schmauss, Max ; Laux, Gerd ; Pfeiffer, Herbert ; Naber, Dieter ; Schmidt, Lutz G. ; Gaebel, Wolfgang ; Klosterkötter, Joachim ; Heuser, Isabella ; Maier, Wolfgang ; Lemke, Matthias R. ; Rüther, Eckart ; Klingberg, Stefan ; Gastpar, Markus ; Möller, Hans-Jürgen</creatorcontrib><description>The aim of this study was to evaluate residual symptoms in patients achieving remission according to the consensus criteria and to analyze their potential influence on the patient’s outcome one year after discharge. In total, 399 patients suffering from a schizophrenia spectrum disorder were evaluated within a naturalistic study. Remission status was examined using the consensus criteria. Residual symptoms were defined as any symptom present at the time-point of remission following analogous analyses performed in depressed patients. Therefore, a PANSS item with a symptom severity of >1 (= at least borderline mentally ill) was defined to be a residual symptom. Remitters with and without residual symptoms were compared regarding psychopathology, functioning and side effects. In total, 236 patients (59 %) were remitters at discharge with 94 % of them suffering from at least one residual symptom. The most common residual symptoms were blunted affect (49 %), conceptual disorganization (42 %) and social withdrawal (40 %). A significant association was found between the presence of residual symptoms and the severity of side effects (
p
< 0.0001) and functioning (
p
= 0.0003) at discharge as well as between residual symptoms and the risk of relapse and chance of remission one year after discharge. Residual symptoms were highly prevalent in remitted schizophrenia inpatients following the suggested definition. Most residual symptoms were persistent baseline symptoms suggesting an ongoing illness severity. Also, the necessity to re-evaluate the consensus criteria questioning the status of remission in these patients is also pointed out.</description><identifier>ISSN: 0940-1334</identifier><identifier>EISSN: 1433-8491</identifier><identifier>DOI: 10.1007/s00406-014-0528-2</identifier><identifier>PMID: 25261210</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Adult ; Analysis of Variance ; Antipsychotic Agents - therapeutic use ; Diagnostic and Statistical Manual of Mental Disorders ; Female ; Follow-Up Studies ; Humans ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Neurosciences ; Original Paper ; Psychiatric Status Rating Scales ; Psychiatry ; Psychopathology ; Psychotic Disorders - complications ; Psychotic Disorders - diagnosis ; Psychotic Disorders - drug therapy ; Recurrence ; Retrospective Studies ; Schizophrenia - complications ; Schizophrenia - diagnosis ; Schizophrenia - drug therapy ; Schizophrenic Psychology</subject><ispartof>European archives of psychiatry and clinical neuroscience, 2015-03, Vol.265 (2), p.107-116</ispartof><rights>Springer-Verlag Berlin Heidelberg 2014</rights><rights>Springer-Verlag Berlin Heidelberg 2015</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c475t-cd988d885d74faf535de1119f22d7c1b2aba97c4c755ac8910f399313ea2fa023</citedby><cites>FETCH-LOGICAL-c475t-cd988d885d74faf535de1119f22d7c1b2aba97c4c755ac8910f399313ea2fa023</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00406-014-0528-2$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00406-014-0528-2$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25261210$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Schennach, Rebecca</creatorcontrib><creatorcontrib>Riedel, Michael</creatorcontrib><creatorcontrib>Obermeier, Michael</creatorcontrib><creatorcontrib>Spellmann, Ilja</creatorcontrib><creatorcontrib>Musil, Richard</creatorcontrib><creatorcontrib>Jäger, Markus</creatorcontrib><creatorcontrib>Schmauss, Max</creatorcontrib><creatorcontrib>Laux, Gerd</creatorcontrib><creatorcontrib>Pfeiffer, Herbert</creatorcontrib><creatorcontrib>Naber, Dieter</creatorcontrib><creatorcontrib>Schmidt, Lutz G.</creatorcontrib><creatorcontrib>Gaebel, Wolfgang</creatorcontrib><creatorcontrib>Klosterkötter, Joachim</creatorcontrib><creatorcontrib>Heuser, Isabella</creatorcontrib><creatorcontrib>Maier, Wolfgang</creatorcontrib><creatorcontrib>Lemke, Matthias R.</creatorcontrib><creatorcontrib>Rüther, Eckart</creatorcontrib><creatorcontrib>Klingberg, Stefan</creatorcontrib><creatorcontrib>Gastpar, Markus</creatorcontrib><creatorcontrib>Möller, Hans-Jürgen</creatorcontrib><title>What are residual symptoms in schizophrenia spectrum disorder? Clinical description and 1-year persistence within a naturalistic trial</title><title>European archives of psychiatry and clinical neuroscience</title><addtitle>Eur Arch Psychiatry Clin Neurosci</addtitle><addtitle>Eur Arch Psychiatry Clin Neurosci</addtitle><description>The aim of this study was to evaluate residual symptoms in patients achieving remission according to the consensus criteria and to analyze their potential influence on the patient’s outcome one year after discharge. In total, 399 patients suffering from a schizophrenia spectrum disorder were evaluated within a naturalistic study. Remission status was examined using the consensus criteria. Residual symptoms were defined as any symptom present at the time-point of remission following analogous analyses performed in depressed patients. Therefore, a PANSS item with a symptom severity of >1 (= at least borderline mentally ill) was defined to be a residual symptom. Remitters with and without residual symptoms were compared regarding psychopathology, functioning and side effects. In total, 236 patients (59 %) were remitters at discharge with 94 % of them suffering from at least one residual symptom. The most common residual symptoms were blunted affect (49 %), conceptual disorganization (42 %) and social withdrawal (40 %). A significant association was found between the presence of residual symptoms and the severity of side effects (
p
< 0.0001) and functioning (
p
= 0.0003) at discharge as well as between residual symptoms and the risk of relapse and chance of remission one year after discharge. Residual symptoms were highly prevalent in remitted schizophrenia inpatients following the suggested definition. Most residual symptoms were persistent baseline symptoms suggesting an ongoing illness severity. Also, the necessity to re-evaluate the consensus criteria questioning the status of remission in these patients is also pointed out.</description><subject>Adult</subject><subject>Analysis of Variance</subject><subject>Antipsychotic Agents - therapeutic use</subject><subject>Diagnostic and Statistical Manual of Mental Disorders</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Neurosciences</subject><subject>Original Paper</subject><subject>Psychiatric Status Rating Scales</subject><subject>Psychiatry</subject><subject>Psychopathology</subject><subject>Psychotic Disorders - complications</subject><subject>Psychotic Disorders - diagnosis</subject><subject>Psychotic Disorders - drug therapy</subject><subject>Recurrence</subject><subject>Retrospective Studies</subject><subject>Schizophrenia - complications</subject><subject>Schizophrenia - diagnosis</subject><subject>Schizophrenia - drug therapy</subject><subject>Schizophrenic Psychology</subject><issn>0940-1334</issn><issn>1433-8491</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqNkU2LFDEQhoMo7rj6A7xIwIuXdqvSSX-cRAa_YGEvisemJkk7WbrTbSrNMv4Af_f2OKuIIOypIPW8bxIeIZ4jvEaA-oIBNFQFoC7AqKZQD8QGdVkWjW7xodhAq6HAstRn4gnzNQCgUfBYnCmjKlQIG_Hz656ypORl8hzcQoPkwzjnaWQZomS7Dz-meZ98DCR59janZZQu8JScT2_kdggx2DXlPNsU5hymKCk6icXBU5KzTxw4-2i9vAl5v3aSjJSXRMN6HqzMKdDwVDzqaWD_7G6eiy_v333efiwurz582r69LKyuTS6sa5vGNY1xte6pN6VxHhHbXilXW9wp2lFbW21rY8g2LUJftm2JpSfVE6jyXLw69c5p-r54zt0Y2PphoOinhTusKq3QILT3QE1TQ6XMEX35D3o9LSmuH_lFrW5MY1YKT5RNE3PyfTenMFI6dAjd0Wd38tmtPrujz-743hd3zctu9O5P4rfAFVAngNdV_ObTX1f_t_UWRZmsUA</recordid><startdate>20150301</startdate><enddate>20150301</enddate><creator>Schennach, Rebecca</creator><creator>Riedel, Michael</creator><creator>Obermeier, Michael</creator><creator>Spellmann, Ilja</creator><creator>Musil, Richard</creator><creator>Jäger, Markus</creator><creator>Schmauss, Max</creator><creator>Laux, Gerd</creator><creator>Pfeiffer, Herbert</creator><creator>Naber, Dieter</creator><creator>Schmidt, Lutz G.</creator><creator>Gaebel, Wolfgang</creator><creator>Klosterkötter, Joachim</creator><creator>Heuser, Isabella</creator><creator>Maier, Wolfgang</creator><creator>Lemke, Matthias R.</creator><creator>Rüther, Eckart</creator><creator>Klingberg, Stefan</creator><creator>Gastpar, Markus</creator><creator>Möller, Hans-Jürgen</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20150301</creationdate><title>What are residual symptoms in schizophrenia spectrum disorder? Clinical description and 1-year persistence within a naturalistic trial</title><author>Schennach, Rebecca ; Riedel, Michael ; Obermeier, Michael ; Spellmann, Ilja ; Musil, Richard ; Jäger, Markus ; Schmauss, Max ; Laux, Gerd ; Pfeiffer, Herbert ; Naber, Dieter ; Schmidt, Lutz G. ; Gaebel, Wolfgang ; Klosterkötter, Joachim ; Heuser, Isabella ; Maier, Wolfgang ; Lemke, Matthias R. ; Rüther, Eckart ; Klingberg, Stefan ; Gastpar, Markus ; Möller, Hans-Jürgen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c475t-cd988d885d74faf535de1119f22d7c1b2aba97c4c755ac8910f399313ea2fa023</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adult</topic><topic>Analysis of Variance</topic><topic>Antipsychotic Agents - therapeutic use</topic><topic>Diagnostic and Statistical Manual of Mental Disorders</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Neurosciences</topic><topic>Original Paper</topic><topic>Psychiatric Status Rating Scales</topic><topic>Psychiatry</topic><topic>Psychopathology</topic><topic>Psychotic Disorders - complications</topic><topic>Psychotic Disorders - diagnosis</topic><topic>Psychotic Disorders - drug therapy</topic><topic>Recurrence</topic><topic>Retrospective Studies</topic><topic>Schizophrenia - complications</topic><topic>Schizophrenia - diagnosis</topic><topic>Schizophrenia - drug therapy</topic><topic>Schizophrenic Psychology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schennach, Rebecca</creatorcontrib><creatorcontrib>Riedel, Michael</creatorcontrib><creatorcontrib>Obermeier, Michael</creatorcontrib><creatorcontrib>Spellmann, Ilja</creatorcontrib><creatorcontrib>Musil, Richard</creatorcontrib><creatorcontrib>Jäger, Markus</creatorcontrib><creatorcontrib>Schmauss, Max</creatorcontrib><creatorcontrib>Laux, Gerd</creatorcontrib><creatorcontrib>Pfeiffer, Herbert</creatorcontrib><creatorcontrib>Naber, Dieter</creatorcontrib><creatorcontrib>Schmidt, Lutz G.</creatorcontrib><creatorcontrib>Gaebel, Wolfgang</creatorcontrib><creatorcontrib>Klosterkötter, Joachim</creatorcontrib><creatorcontrib>Heuser, Isabella</creatorcontrib><creatorcontrib>Maier, Wolfgang</creatorcontrib><creatorcontrib>Lemke, Matthias R.</creatorcontrib><creatorcontrib>Rüther, Eckart</creatorcontrib><creatorcontrib>Klingberg, Stefan</creatorcontrib><creatorcontrib>Gastpar, Markus</creatorcontrib><creatorcontrib>Möller, Hans-Jürgen</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>European archives of psychiatry and clinical neuroscience</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schennach, Rebecca</au><au>Riedel, Michael</au><au>Obermeier, Michael</au><au>Spellmann, Ilja</au><au>Musil, Richard</au><au>Jäger, Markus</au><au>Schmauss, Max</au><au>Laux, Gerd</au><au>Pfeiffer, Herbert</au><au>Naber, Dieter</au><au>Schmidt, Lutz G.</au><au>Gaebel, Wolfgang</au><au>Klosterkötter, Joachim</au><au>Heuser, Isabella</au><au>Maier, Wolfgang</au><au>Lemke, Matthias R.</au><au>Rüther, Eckart</au><au>Klingberg, Stefan</au><au>Gastpar, Markus</au><au>Möller, Hans-Jürgen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>What are residual symptoms in schizophrenia spectrum disorder? Clinical description and 1-year persistence within a naturalistic trial</atitle><jtitle>European archives of psychiatry and clinical neuroscience</jtitle><stitle>Eur Arch Psychiatry Clin Neurosci</stitle><addtitle>Eur Arch Psychiatry Clin Neurosci</addtitle><date>2015-03-01</date><risdate>2015</risdate><volume>265</volume><issue>2</issue><spage>107</spage><epage>116</epage><pages>107-116</pages><issn>0940-1334</issn><eissn>1433-8491</eissn><abstract>The aim of this study was to evaluate residual symptoms in patients achieving remission according to the consensus criteria and to analyze their potential influence on the patient’s outcome one year after discharge. In total, 399 patients suffering from a schizophrenia spectrum disorder were evaluated within a naturalistic study. Remission status was examined using the consensus criteria. Residual symptoms were defined as any symptom present at the time-point of remission following analogous analyses performed in depressed patients. Therefore, a PANSS item with a symptom severity of >1 (= at least borderline mentally ill) was defined to be a residual symptom. Remitters with and without residual symptoms were compared regarding psychopathology, functioning and side effects. In total, 236 patients (59 %) were remitters at discharge with 94 % of them suffering from at least one residual symptom. The most common residual symptoms were blunted affect (49 %), conceptual disorganization (42 %) and social withdrawal (40 %). A significant association was found between the presence of residual symptoms and the severity of side effects (
p
< 0.0001) and functioning (
p
= 0.0003) at discharge as well as between residual symptoms and the risk of relapse and chance of remission one year after discharge. Residual symptoms were highly prevalent in remitted schizophrenia inpatients following the suggested definition. Most residual symptoms were persistent baseline symptoms suggesting an ongoing illness severity. Also, the necessity to re-evaluate the consensus criteria questioning the status of remission in these patients is also pointed out.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>25261210</pmid><doi>10.1007/s00406-014-0528-2</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0940-1334 |
| ispartof | European archives of psychiatry and clinical neuroscience, 2015-03, Vol.265 (2), p.107-116 |
| issn | 0940-1334 1433-8491 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1664215109 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Adult Analysis of Variance Antipsychotic Agents - therapeutic use Diagnostic and Statistical Manual of Mental Disorders Female Follow-Up Studies Humans Male Medicine Medicine & Public Health Middle Aged Neurosciences Original Paper Psychiatric Status Rating Scales Psychiatry Psychopathology Psychotic Disorders - complications Psychotic Disorders - diagnosis Psychotic Disorders - drug therapy Recurrence Retrospective Studies Schizophrenia - complications Schizophrenia - diagnosis Schizophrenia - drug therapy Schizophrenic Psychology |
| title | What are residual symptoms in schizophrenia spectrum disorder? Clinical description and 1-year persistence within a naturalistic trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T04%3A45%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=What%20are%20residual%20symptoms%20in%20schizophrenia%20spectrum%20disorder?%20Clinical%20description%20and%201-year%20persistence%20within%20a%20naturalistic%20trial&rft.jtitle=European%20archives%20of%20psychiatry%20and%20clinical%20neuroscience&rft.au=Schennach,%20Rebecca&rft.date=2015-03-01&rft.volume=265&rft.issue=2&rft.spage=107&rft.epage=116&rft.pages=107-116&rft.issn=0940-1334&rft.eissn=1433-8491&rft_id=info:doi/10.1007/s00406-014-0528-2&rft_dat=%3Cproquest_cross%3E1664215109%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1658052585&rft_id=info:pmid/25261210&rfr_iscdi=true |